A Randomized, Placebo-controlled, Double-blind, Multicenter, 12-Week, 3-Way, Partial-replicate Crossover Pharmacodynamic Study to Assess the Equivalence of Budesonide and Albuterol (BDA) Delivered by MDI HFO Compared With BDA Delivered by MDI HFA in Participants With Asthma
Latest Information Update: 16 Feb 2026
At a glance
- Drugs Budesonide/salbutamol (Primary)
- Indications Asthma
- Focus Therapeutic Use
- Sponsors AstraZeneca
Most Recent Events
- 13 Feb 2026 Status changed from recruiting to active, no longer recruiting.
- 12 Dec 2024 Planned End Date changed from 24 Feb 2026 to 3 Mar 2026.
- 12 Dec 2024 Planned primary completion date changed from 24 Feb 2026 to 3 Mar 2026.